[go: up one dir, main page]

DK0868519T3 - Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser - Google Patents

Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Info

Publication number
DK0868519T3
DK0868519T3 DK96940870T DK96940870T DK0868519T3 DK 0868519 T3 DK0868519 T3 DK 0868519T3 DK 96940870 T DK96940870 T DK 96940870T DK 96940870 T DK96940870 T DK 96940870T DK 0868519 T3 DK0868519 T3 DK 0868519T3
Authority
DK
Denmark
Prior art keywords
aur
polypeptides
diagnosis
treatment
related disorders
Prior art date
Application number
DK96940870T
Other languages
English (en)
Inventor
Gregory D Plowman
Kevin G Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0868519(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK0868519T3 publication Critical patent/DK0868519T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK96940870T 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser DK0868519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14

Publications (1)

Publication Number Publication Date
DK0868519T3 true DK0868519T3 (da) 2006-05-08

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96940870T DK0868519T3 (da) 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Country Status (15)

Country Link
US (2) US5962312A (da)
EP (2) EP1655369A1 (da)
JP (1) JP3944241B2 (da)
KR (1) KR100459052B1 (da)
AT (1) ATE315654T1 (da)
AU (1) AU716330B2 (da)
CA (1) CA2239692C (da)
DE (1) DE69635740T2 (da)
DK (1) DK0868519T3 (da)
ES (1) ES2255715T3 (da)
IL (1) IL124728A (da)
NO (1) NO323646B1 (da)
NZ (1) NZ323795A (da)
PT (1) PT868519E (da)
WO (1) WO1997022702A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
AU8649698A (en) * 1997-08-15 1999-03-08 Chugai Seiyaku Kabushiki Kaisha Cell cycle-regulating proteins
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
WO2003083096A2 (en) * 2002-03-28 2003-10-09 Qlt Inc. Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
SI1546182T1 (sl) * 2002-09-11 2011-04-29 Genentech Inc Sestavki in postopki za diagnozo in zdravljenje tumorja
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
DE60328735D1 (de) 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP4568716B2 (ja) * 2003-02-20 2010-10-27 ジェノミック ヘルス, インコーポレイテッド 遺伝子発現を測定するためのイントロンrnaの使用
EP2226396A1 (en) * 2003-05-30 2010-09-08 Genomic Health, Inc. Gene expression markers for response to EGFR inhibitor drugs
EP1641810B2 (en) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
AU2004284434A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ES2360113T3 (es) * 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
WO2006052731A2 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
ES2778851T3 (es) * 2004-11-05 2020-08-12 Genomic Health Inc Predicción de la respuesta a la quimioterapia mediante el uso de marcadores de expresión génica
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2006108489A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080020412A1 (en) * 2006-01-03 2008-01-24 Romanowski Michael J Aurora expression constructs
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Hla−a2拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
EP0703984A1 (en) * 1993-04-07 1996-04-03 Cancer Research Campaign Technology Limited Methods for screening of substances for therapeutic activity and yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
JP3944241B2 (ja) 2007-07-11
CA2239692A1 (en) 1997-06-26
CA2239692C (en) 2008-12-16
JP2000502895A (ja) 2000-03-14
WO1997022702A1 (en) 1997-06-26
PT868519E (pt) 2006-05-31
EP0868519A1 (en) 1998-10-07
NZ323795A (en) 2000-01-28
ES2255715T3 (es) 2006-07-01
US5962312A (en) 1999-10-05
IL124728A (en) 2007-06-03
US5972676A (en) 1999-10-26
AU1082697A (en) 1997-07-14
EP0868519B1 (en) 2006-01-11
DE69635740T2 (de) 2006-09-14
AU716330B2 (en) 2000-02-24
NO982794L (no) 1998-08-18
ATE315654T1 (de) 2006-02-15
NO323646B1 (no) 2007-06-18
NO982794D0 (no) 1998-06-17
IL124728A0 (en) 1999-01-26
KR20000064437A (ko) 2000-11-06
KR100459052B1 (ko) 2005-01-15
EP1655369A1 (en) 2006-05-10
DE69635740D1 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
DE69323765D1 (de) Säugetier-rezeptoren für interleukin 10 (il-10)
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
BR9302075A (pt) Composto de aminoacido,composto de acido nucleico,vetor de acido nucleico,celula hospedeira,clone genomico,processo para diagnostico de doenca de alzheimer,teste,e processo para expressar uma sequencia de acido nucleico
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
DK1015477T3 (da) 32 humane sekreterede proteiner
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69841037D1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DK1086225T3 (da) Humant tumorafledt polypeptidhormon phosphatonin
DE69943022D1 (de) Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE265533T1 (de) Saeugetierchemokine
WO1999033870A3 (en) Human regulatory proteins
DE3751893D1 (de) Polypeptid und dessen Herstellung
WO2004042000A3 (en) 157 human secreted proteins
DE69734890D1 (de) Rdgb-proteine
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
KR880701886A (ko) 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링